Estrogen Receptor Positive Breast Cancer clinical trials

Explore recruiting estrogen receptor positive breast cancer clinical trials.

Recruiting estrogen receptor positive breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Estrogen Receptor Positive Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Unravelling the local and systemic effects of primary surgery and perioperative use of ketorolac and pregabalin in primary breast cancer patients according to adiposity

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients “CARABELA Study”

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2- ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK4/6 INHIBITOR THERAPY (OPERA-01)

Italy, Bulgaria, Belgium, Austria, Romania, Germany +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

GERICO11_Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine treatment. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial

Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Estrogen Receptor Positive Breast Cancer trials by city

Estrogen Receptor Positive Breast Cancer in Toronto Estrogen Receptor Positive Breast Cancer in Vancouver Estrogen Receptor Positive Breast Cancer in Montreal Estrogen Receptor Positive Breast Cancer in Calgary Estrogen Receptor Positive Breast Cancer in Edmonton Estrogen Receptor Positive Breast Cancer in Ottawa Estrogen Receptor Positive Breast Cancer in Winnipeg Estrogen Receptor Positive Breast Cancer in Quebec City Estrogen Receptor Positive Breast Cancer in Hamilton Estrogen Receptor Positive Breast Cancer in Kitchener Estrogen Receptor Positive Breast Cancer in London Estrogen Receptor Positive Breast Cancer in Halifax Estrogen Receptor Positive Breast Cancer in New York Estrogen Receptor Positive Breast Cancer in Los Angeles Estrogen Receptor Positive Breast Cancer in Chicago Estrogen Receptor Positive Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease